4 results  1 of 1 

1 Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis
Kazufumi Dohmen, Shin-ya Onohara, Shigeru Harada
Korean J Gastroenterol.2021;78(4):227-234.   Published online 2021 October 25     DOI: http://dx.doi.org/10.4166/kjg.2021.092
      
2 HDL Cholesterol Reduction during Rosiglitazone and Fenofibrate Treatment in a Type 2 Diabetes Mellitus Patient with Dyslipidemia
Mijeong Im, Minki Kim, Jin Kyung Lee, Yoon Hwan Chang, Dong Young Lee, Seok-Il Hong, Yun Yong Lee, Young Jun Hong
Korean J Lab Med.2010;30(1):17-19.   Published online 2010 January 14     DOI: http://dx.doi.org/10.3343/kjlm.2010.30.1.17
   
3 Postprandial Hypertriglyceridemia Following a Single High-Fat Meal in Patients with Coronary Artery Disease and Normal Subjects: The Significance of the Postprandial Hypertriglyceridemia and the Effects of Fibrate on the Postprandial Hypertriglyceridemia
Jang Ho Bae, Kwon Bae Kim, Hee Ja Lee, Kee Sik Kim, Yoon Nyun Kim, In Kyu Lee, In Soo Huh, Jin Sook Yoon, Chang Wook Nam, Weon Seung Shin, Shee Juhn Chung
Korean Circ J.1999;29(7):680-687.   Published online 1999 July 31     DOI: http://dx.doi.org/10.4070/kcj.1999.29.7.680
      
4 Efficacy of Ciprofibrate Monotherapy in Patients with Type II and Type IV Hyperlipidemia
Sang-Gon Lee, Jae-Joong Kim, Hye Soon Park, Jae-Kwan Song, Seong-Wook Park, Seung-Jung Park, Simon Jong-Koo Lee
Korean Circ J.1995;25(4):855-860.   Published online 1995 August 31     DOI: http://dx.doi.org/10.4070/kcj.1995.25.4.855
      

 1 of 1